MedTrace Logo

Mildronate for Acute Ischemic Stroke

NCT01831011 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2013-04-12

No results posted yet for this study

Summary

Mildronate an inhibitor of carnitine-dependent metabolism, is considered an anti-ischemic drug. This study aims to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

mildronate injection

DRUG

cinepazide maleate injection

DRUG

aspirin

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Gang Zhao, MD · the Department of Neurology , Xijing Hospital

  • Guang Yun Zhang, MD · the Department of Neurology , Xijing Hospital

  • Yi Zhu, MD · the Department of Neurology , Xijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01831011 on ClinicalTrials.gov